Cardiac Interventions Today

Edwards Sapien M3 Transseptal TMVR System Approved by FDA - Cardiac Interventions Today December 23, 2025—Edwards Lifesciences announced FDA approval for the company’s Sapien M3 transcatheter mitral valve replacement (TMVR) sy

Edwards Sapien M3 Transseptal TMVR System Approved by FDA
citoday.com/news/edwards...

Radiation Exposure Reduction Studied With EggNest Complete System - Cardiac Interventions Today October 31, 2025—Egg Medical, Inc. announced the presentation of real-world studies demonstrating that the company’s EggNest Complete radi

Radiation Exposure Reduction Studied With EggNest Complete System
citoday.com/news/radiati...

CMS Finalizes National Coverage Determination for Renal Denervation Systems - Endovascular Today October 29, 2025—The Centers for Medicare & Medicaid Services (CMS) has released the final National Coverage Determination (NCD) on renal de

CMS Finalizes National Coverage Determination for Renal Denervation Systems
evtoday.com/news/cms-fin...

Penumbra’s CAVT With Anticoagulation Studied in STORM-PE - Endovascular Today October 27, 2025—Penumbra, Inc. announced that the results of the STORM-PE randomized controlled trial showed that mechanical thrombectomy using

Penumbra’s CAVT With Anticoagulation Studied in STORM-PE
evtoday.com/news/penumbr...

Imperative Care Presents Symphony Thrombectomy System Pivotal Trial in Acute PE - Endovascular Today September 18, 2025—Imperative Care, Inc. announced efficacy and safety results from the pivotal SYMPHONY-PE trial. The prospective, multicenter

Imperative Care Presents Symphony Thrombectomy System Pivotal Trial in Acute PE

evtoday.com/news/imperat...

Laza’s AI Heart Model Marks FIH Use in Ultrasound-Guided Cardiac Procedures  - Cardiac Interventions Today September 3, 2025—Laza Medical, Inc., which is developing artificial intelligence (AI)–powered robotic ultrasound image guidance technolog

Laza’s AI Heart Model Marks FIH Use in Ultrasound-Guided Cardiac Procedures

Imperative Care’s Symphony Thrombectomy System Cleared for PE - Cardiac Interventions Today September 2, 2025—Imperative Care, Inc. announced it has received FDA 510(k) clearance of its Symphony thrombectomy system to treat pulmonary em

Imperative Care Symphony Thrombectomy System Cleared for PE

Artrya’s Salix Coronary Plaque Module Cleared by FDA - Cardiac Interventions Today August 25, 2025—Artrya Limited announced it has received 510(k) clearance from the FDA for the Salix coronary plaque module. The module is part

Artrya’s Salix Coronary Plaque Module Cleared by FDA

FDA Begins Real-Time Reporting of Adverse Event Data - Cardiac Interventions Today August 25, 2025—The FDA announced it has commenced daily publication of adverse event data from the FDA Adverse Event Reporting System (FAERS).

FDA Begins Real-Time Reporting of Adverse Event Data

Otsuka Medical Devices Announces Japan Approval of Paradise uRDN System - Cardiac Interventions Today August 25, 2025—Otsuka Medical Devices Co., Ltd. announced that the Paradise ultrasound renal denervation (uRDN) system has received manufacturi

Otsuka Medical Devices Announces Japan Approval of Paradise uRDN System
citoday.com/news/otsuka-...

Gentuity and GE HealthCare to Collaborate on Intravascular Imaging Platform Commercialization - Cardiac Interventions Today August 11, 2025—Gentuity LLC, a developer of intravascular imaging devices, recently announced an agreement with GE HealthCare to collaborate on

Gentuity and GE HealthCare to Collaborate on Intravascular Imaging Platform Commercialization

A Decade of Quality Improvement: The National Cardiogenic Shock Initiative - Cardiac Interventions Today Babar Basir, DO, FACC, FSCAI, shares insights into the development and growth of the NCSI, discussing its impact on cardiogenic shock care over the past 10 years, as well as future endeavors.

In our conversation with Dr. Babar Basir, he recounts the impact of the first decade of The National Cardiogenic Shock Initiative and shares insights into what’s on the horizon for this initiative.

A Cardiogenic Shock Challenge: Achieving 24-Hour Door-to-Lactate Clearance - Cardiac Interventions Today SCAI President Srihari S. Naidu, MD, is challenging the interventional cardiology field and all members of the shock team to achieve a door-to-lactate clearance of 24 hours to improve cardiogenic shoc...

We spoke with SCAI President Srihari S. Naidu, MD, about his ambitious passion project in challenging the interventional cardiology field to achieve a 24-hour door-to-lactate clearance in cardiogenic shock care. @scainews.bsky.social

Biosensors Imperia Delivery System Receives CE Mark Approval - Cardiac Interventions Today July 17, 2025—Biosensors International recently announced it received CE Mark certification for the Imperia delivery system under the European U

Biosensors Imperia Delivery System Receives CE Mark Approval

CMS Approves Coverage for T-TEER to Treat Tricuspid Regurgitation - Cardiac Interventions Today July 11, 2025—The United States Centers for Medicare & Medicaid Services (CMS) recently announced it has issued a National Coverage Determin

CMS Approves Coverage for T-TEER to Treat Tricuspid Regurgitation

Medtronic’s SPYRAL GEMINI Multiorgan Denervation Study Begins Enrollment - Endovascular Today July 7, 2025—Medtronic announced that the first patient has been treated in its SPYRAL GEMINI global pilot study, which will investigate the saf

Medtronic’s SPYRAL GEMINI Multiorgan Denervation Study Begins Enrollment
evtoday.com/news/medtron...

MiRus Siegel 8-F TAVR System Evaluated in Early Feasibility Study - Cardiac Interventions Today July 2, 2025—MiRus, LLC, announced the presentation of 30-day results from the United States early feasibility study (EFS) of the company’

MiRus Siegel 8-F TAVR System Evaluated in Early Feasibility Study

Foldax Tria Mitral Valve Evaluated in Clinical Trial - Cardiac Interventions Today June 27, 2025—Foldax Inc., a Utah-based developer of polymer heart valves, announced 1-year results from a clinical trial in India of the compan

Foldax Tria Mitral Valve Evaluated in Clinical Trial
citoday.com/news/foldaxs...

Evoque Tricuspid Valve Replacement System From Edwards Approved in Canada - Cardiac Interventions Today June 24, 2025—Edwards Lifesciences Corporation announced that the company’s Evoque tricuspid valve replacement system has received Health

Evoque Tricuspid Valve Replacement System From Edwards Lifesciences Approved in Canada citoday.com/news/edwards...

Radiation and Musculoskeletal Safety - Cardiac Interventions Today As interventional cardiologists, we are tasked with providing the best care to our patients, oftentimes while putting our own health and safety at

Our new issue, introduced by Eric A. Secemsky, MD, explores what we know and what we can learn about radiation and musculoskeletal safety and how we can protect ourselves. PLUS: Hypertension therapy.
citoday.com/articles/202...

Building a Cardio-Oncology Practice - Cardiac Interventions Today A discussion of first steps, getting buy-in from administration and colleagues, essential support staff and service lines, building and maintaining relationships, obtaining referrals, raising awarenes...

In a roundtable discussion, Drs. Eric H. Yang and Ashley Stein-Merlob from the UCLA Cardio-Oncology Program do a deep dive into building a #cardioonc practice
citoday.com/articles/202...

ACC and BIDMC Smith Center Collaborate on Renal Denervation Registry - Endovascular Today June 10, 2025—The American College of Cardiology (ACC) reported that the Richard A. and Susan F. Smith Center for Outcomes Research at Beth Isra

ACC and BIDMC Smith Center Collaborate on Renal Denervation Registry
evtoday.com/news/acc-and...

1-Year Results Reported for Jenscare JensClip - Cardiac Interventions Today June 9, 2025—Jenscare Scientific Co., Ltd. recently announced that 1-year outcomes from a study of the JensClip transcatheter mitral valve repla

1-Year Results Reported for Jenscare JensClip | #EuroPCR2025
citoday.com/news/1-year-...

Future Focus: Predictions for the Cardio-Oncology Field in 10 Years - Cardiac Interventions Today The next decade of cardio-oncology is likely to include an increased presence in training programs, more outcomes data for intervention in specific cardiovascular presentations, improved patient quali...

Predictions from Drs. Orly Leiva Jr and Sara C. Martinez for the future of #cardioonc: increased presence in training programs, more outcomes data, improved QOLs, & greater influence in interventional cardiology. | @leivaorly.bsky.social @entropymama.bsky.social‬

Cardio-Oncology in the Cath Lab The role of the interventional cardiologist, building a practice, and the future of the subspecialty.

In our latest digital exclusive series, we explore cardio-oncology from the lens of the interventional cardiologist. Read more here! #cardioonc

Exploring the Role of Interventional Cardiologists in Cardio-Oncology - Cardiac Interventions Today Leading experts in cardio-oncology discuss where the interventional cardiologist fits in the cardio-oncology field, challenges to treating cancer patients in the cath lab, treatment considerations for...

An interview with leading interventional cardio-oncology experts Mehmet Çilingiroğlu, MD; Konstantinos Marmagkiolis, MD; and Cezar Iliescu, MD, ponders the role of ICs in the #cardioonc field, offers advice for treating cancer patients in the cath lab, and more.

2025 Digital Exclusive No. 2 Issue - Cardiac Interventions Today News and information on minimally invasive coronary disease therapies, covering valvular, structural, radial access, chronic total occlusion, and imaging issues.

🌟 New Issue 🌟 Our digital exclusive series looks at cardio-oncology from the lens of an interventional cardiologist, with expert insights on treating cancer patients in the cath lab, predictions for the next decade, & building your own practice. #cardioonc

Abbott’s Tendyne TMVR System Approved by FDA - Cardiac Interventions Today May 27, 2025—Abbott announced FDA approval of the company’s Tendyne transcatheter mitral valve replacement (TMVR) system for the treatment

Abbott’s Tendyne TMVR System Approved by FDA
citoday.com/news/abbotts...

TAVR for AR Spotlight: Do We Have a Pacemaker Issue? - Cardiac Interventions Today Challenges with nondedicated and dedicated devices, uncertain predictors, and long-term implications.

Hendrik Wienemann, MD, addresses a critical procedural question: Do we have a pacing problem in TAVR for AR? As the need for postprocedural pacemakers may be higher in this subset, implications for long-term outcomes warrant close attention.
citoday.com/articles/202...